Expression of truncated HER2 and its prognostic value in HER2-positive breast cancer patients
| Autor: | Mohamed El-Shebiney, Yomna A. Zamzam, Alaa Maria, Ayman Mohamed Elsaka |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
0301 basic medicine Oncology medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Breast Neoplasms Kaplan-Meier Estimate lcsh:RC254-282 Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Breast cancer Trastuzumab Internal medicine Biomarkers Tumor Materials Chemistry medicine Adjuvant therapy Humans skin and connective tissue diseases Receptor neoplasms Aged Chemotherapy business.industry Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis medicine.disease Immunohistochemistry Regimen 030104 developmental biology Drug Resistance Neoplasm 030220 oncology & carcinogenesis Female business Adjuvant medicine.drug |
| Zdroj: | Journal of the Egyptian National Cancer Institute, Vol 30, Iss 2, Pp 49-55 (2018) |
| ISSN: | 1110-0362 |
| Popis: | Purpose: The purpose of this work was to assess the truncated form of human epidermal growth factor receptor 2 (HER2) such as p95-HER2 expression in HER2-positive breast cancer (BC) patients who developed metastatic disease after adjuvant treatment with a trastuzumab-containing regimen. Patients and methods: Thirty-two histologically diagnosed HER2-positive BC patients who developed distant failure after treatment with trastuzumab-based chemotherapy (CT) regimen as an adjuvant therapy were included in the study. Immunohistochemistry (IHC) method was used to analyze p95-HER2 expression in the formalin-fixed, paraffin-embedded (FFPE) blocks of the enrolled patients. Results: p95-HER2 was positive in 34.4% of the patients. The median overall survival (OS) was 22.5 and 35 months for p95-HER2 positive and negative patients, respectively (p = 0.036) and the median time to metastases was 14 and 21 months, respectively (p = 0.006). There was a statistically significant association between positive p95-HER2 expression and negative hormonal receptors expression (p = 0.004), high Ki-67 expression (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|